Cortical and subcortical connections change after repetitive transcranial magnetic stimulation therapy in cocaine use disorder and predict clinical outcome

Abstract

Cocaine use disorder (CUD) is a worldwide public health condition which is suggested to induce pathological changes in macro- and microstructure. Treatments with psychosocial and pharmacological approaches achieve only low to moderate effects on dealing with cocaine clinical symptomatology. Novel approaches such as repetitive transcranial magnetic stimulation (rTMS) have gained attention to induce a reduction in CUD symptoms, yet its mechanisms remain partially understood. Here, we sought to elucidate whether rTMS induces changes on white matter (WM) microstructure in frontostriatal circuits after two weeks of therapy in patients with CUD, and to test whether baseline WM microstructure of the same circuits has an effect on clinical improvement. This study consisted of a 2-week, parallel group, double-blind, randomized controlled clinical trial (acute phase) (sham [n = 23] and active [n = 27]), in which patients received two daily sessions of rTMS on the left dorsolateral prefrontal cortex (lDLPFC) as an add-on treatment. We acquired T1-weighted and HARDI-DWI 2-shell sequences at baseline and at two weeks. To elucidate the effects from active rTMS on frontostriatal WM tracts, we extracted NODDI metrics and performed a linear mixed model. We further evaluated the relationship between clinical outcomes in craving and impulsivity and the baseline white matter microstructure. After 2 weeks, active rTMS showed a significant increase in neurite density (ICVF or the density of axons and dendrites) compared to sham rTMS in WM tracts connecting left DLPFC with left (B = 0.038, d = -0.278) and right vmPFC (B = 0.034, d = -0.112). Similarly, rTMS showed reduction in orientation dispersion (OD or axon organization) in WM tracts connecting left DLPFC with left caudate nucleus (B = 0.009, d = -0.087), left thalamus (B = 0.006, d = -0.489) and left vmPFC (B = 0.027, d = 0.024). Results also show a greater reduction in craving VAS after 2 weeks rTMS when baseline ICVF was low in WM tracts connecting left caudate nucleus with substantia nigra (B = 22.61, d = 0.729), left pallidum (B = 21.13, d = 0.738), and those connecting left thalamus with substantia nigra (B = 16.30, d = 0.649) and left pallidum (B = 21.92, d = 0.723). Our results suggest that rTMS induced white matter microstructural changes between fronto-striato-thalamic regions after 2 weeks. rTMS-induced microstructural changes may depend on the baseline integrity of the connections between the striatum, thalamus, and the substantia nigra. Connections that predicted clinical improvement in CUD. The current results support the efficacy of rTMS as a therapeutic tool in the treatment of CUD. However, the individual clinical improvement may rely on each patient state of structural connections integrity. Keywords: Cocaine use disorder; Imaging; Transcranial magnetic stimulation; Diffusion MRI; NODDI

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT02986438

Funding Statement

The study was supported by public funds CONACYT FOSISS No. 0260971, CONACYT No. 253072 and PAPIIT-UNAM IA202120. Gabriel Gonzalez-Escamilla is supported by a grant from the German Research Foundation (DFG; CRC-TR-128). Jalil Rasgado-Toledo is a doctoral student from the Programa de Doctorado en Ciencias Biomedicas, Universidad Nacional Autonoma de Mexico (UNAM) and received fellowship 858667 from CONACYT.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Data was obtained from a clinical trial conducted at the Clinical Research Division of the National Institute of Psychiatry in Mexico City, Mexico that was approved by the Institutional Ethics Research Committee (CEI/C/070/2016) and registered at ClinicalTrials.gov (NCT02986438).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

留言 (0)

沒有登入
gif